Moderna Says Remains Comfortable That Its Guided Wide Range Of $6B-$8B For Anticipated Revenues From Sale Of Its Covid-19 Vaccine For Full Year 2023
Portfolio Pulse from Benzinga Newsdesk
Moderna has stated that it remains comfortable with its projected range of $6B-$8B in anticipated revenues from the sale of its Covid-19 vaccine for the full year 2023.
October 16, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's projected revenue from its Covid-19 vaccine sales for 2023 is between $6B and $8B.
The news directly pertains to Moderna's revenue projections for 2023, which is based on the sales of its Covid-19 vaccine. This could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100